<code id='92D4E8D46A'></code><style id='92D4E8D46A'></style>
    • <acronym id='92D4E8D46A'></acronym>
      <center id='92D4E8D46A'><center id='92D4E8D46A'><tfoot id='92D4E8D46A'></tfoot></center><abbr id='92D4E8D46A'><dir id='92D4E8D46A'><tfoot id='92D4E8D46A'></tfoot><noframes id='92D4E8D46A'>

    • <optgroup id='92D4E8D46A'><strike id='92D4E8D46A'><sup id='92D4E8D46A'></sup></strike><code id='92D4E8D46A'></code></optgroup>
        1. <b id='92D4E8D46A'><label id='92D4E8D46A'><select id='92D4E8D46A'><dt id='92D4E8D46A'><span id='92D4E8D46A'></span></dt></select></label></b><u id='92D4E8D46A'></u>
          <i id='92D4E8D46A'><strike id='92D4E8D46A'><tt id='92D4E8D46A'><pre id='92D4E8D46A'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:6383
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Readout Newsletter: Parkinson's study, Gilead, CG Oncology
          Readout Newsletter: Parkinson's study, Gilead, CG Oncology

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          More regulation could be coming for drug ads

          AdobeWASHINGTON—Governmentregulatorsmaysoondecidewhethertocrackdownondistractingvisualsintelevisiond